Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type – 2020 to 2025

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: March 23, 2020
Clear
SKU: GMS-2056 Category:

The global market for vaccines is expected to hit USD 61.32 billion by 2025, rising over the forecast period at a CAGR of 6.65 per cent. This market growth is primarily due to the high prevalence of infectious diseases, increased company efforts to improve vaccine R&D, increased government funding for vaccine production, and increased emphasis on vaccination.

Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type - 2020 to 2025 1

Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type - 2020 to 2025 2

Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type - 2020 to 2025 3

Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type - 2020 to 2025 4

Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type - 2020 to 2025 5

Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type - 2020 to 2025 6

Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type - 2020 to 2025 7

Vaccines Market by Route (Oral, IM, SC, ID), Technology (Recombinant, Live, Toxoid), Disease (DTP, Rotavirus, Pneumococcal, Influenza, MMR, Varicella, Dengue, TT, Polio, Rabies, TB, shingles), Patient (Pediatric, Adult), Type - 2020 to 2025 8

1 Global Vaccines Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 Global Vaccines Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 Global Vaccines Market – Comparative Analysis
4.1 Product Benchmarking – Top 10 companies
4.2 Top 5 Financials Analysis
4.3 Market Value split by Top 10 companies
4.4 Patent Analysis – Top 10 companies
4.5 Pricing Analysis

5 Global Vaccines Market – Industry Market Entry Scenario
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis – Top 10 companies

6 Global Vaccines Market – Market Forces
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.2 Opportunities
6.2.3 Challenges
6.3 Porters Analysis of Market
6.3.1 Bargaining power of suppliers
6.3.2 Bargaining powers of customers
6.3.3 Threat of new entrants
6.3.4 Rivalry among existing players
6.3.5 Threat of substitutes

7 Global Vaccines Market – Strategic Analysis
7.1 Value Chain analysis
7.2 Product Life Cycle
7.3 Supplier and distributor analysis (Market share and product dealing strategies)

8 Global Vaccines Market – By Type (Market Size – & million/billion)
8.1 Monovalent vaccines
8.2 Multivalent vaccines

9 Global Vaccines Market – By Technology
9.1 Conjugate vaccines
9.2 Inactivated and subunit vaccines
9.3 Live attenuated vaccines
9.4 Recombinant vaccines
9.5 Toxoid vaccines

10 Global Vaccines Market – By Patient Type
10.1 Pediatric patients
10.2 Adult patients

11 Global Vaccines Market – By Disease Indication
11.1 Pneumococcal disease
11.2 Meningococcal disease
11.3 Polio
11.4 DTP
11.5 Influenza
11.6 HPV
11.7 Rotavirus
11.8 Hepatitis
11.9 Varicella
11.10 Other

12 Global Vaccines Market – By Route of Administration
12.1 Intramuscular and subcutaneous administration
12.2 Oral administration
12.3 Other

13 Global Vaccines Market – By Geography (Market Size – & million/billion)
13.1 Introduction
13.2 North America
13.2.1 US
13.2.2 Canada
13.2.3 Mexico
13.3 Europe
13.3.1 U.K
13.3.2 Germany
13.3.3 Italy
13.3.4 France
13.3.5 Spain
13.3.6 Rest of Europe
13.4 Asia-Pacific
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 South Korea
13.4.5 Rest of APAC
13.5 Rest of the World
13.5.1 South America
13.5.2 Middle East
13.5.3 Africa

14 Global Vaccines Market – Entropy
14.1 New product launches
14.2 M&A’s, collaborations, JVs and partnerships

15 Global Vaccines Market Company Profile (Key Players)
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Glaxosmithkline PLC
15.3 Pfizer, Inc
15.4 Merck & Co., Inc
15.5 Serum Institute of India Pvt., LTD
15.6 Bavarian Nordic
15.7 Sanofi Pasteur SA
15.8 Johnson & Johnson
15.9 CSL Limited
15.10 Emergent Biosolutions, Inc
15.11 Astrazeneca
15.12 Company 11 & more

16 Global Vaccines Market – Appendix
16.1 Sources
16.2 Abbreviations